Tumor-infiltrating lymphocytes have long been regarded as a promising modality for treating solid tumor cancers with cell therapy, but an ongoing challenge in tapping that potential has been manufacturing. Addressing that, along with defining a regulatory path, will be the key barriers to bringing to market a technology that researchers know is effective at fighting solid tumors, University of Texas MD Anderson Cancer Center'sJason Bock told Scrip.
Vice president and head of biologics development and therapeutic discovery at MD Anderson, Bock said hardly anyone – even at...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
